INTRODUCTION {#s1}
============

Gastric cancer (GC) is an important public health problem worldwide due to its high incidence and mortality. Currently, GC is the fifth most frequently diagnosed cancer, and it is the third most lethal cancer worldwide. Each year, almost one million new cases of GC are diagnosed and more than 700,000 people die of this disease, thereby representing \~10% of the deaths due to cancer worldwide \[[@R1]\]. This high mortality rate is associated with the absence of significant symptoms in the early stages of GC, the lack of validated screening programs, and cancer health care in developing countries, which can be economically or geographically difficult to access. As a result, many cases of GC are diagnosed at an advanced stage and have a poor prognosis.

GC is a complex and multifactorial disease. There are many inherited and environmental factors that play a role in GC carcinogenesis, including the genetic characteristics of the host, infectious agents (such as *Helicobacter pylori* and Epstein Barr), and dietary habits \[[@R2]\]. Correspondingly, GC is a heterogeneous disease, both histologically and genetically, and patient outcome is difficult to predict using just the classical histologic and molecular classification criteria \[[@R3]\]. The current histologic classification of GC is well accepted and several molecular analyses have associated the genetic and epigenetic alterations with the prognosis and diagnosis of advanced stage patients. However, the prognosis and predictive capacity of this system do not adequately guide patient management, thereby necessitating the development of robust classifiers \[[@R4], [@R5]\]. Recent advances in high-throughput technologies, including microarrays and next-generation sequencing, have led to the discovery of new molecular markers, intracellular pathways, and molecular subtypes of GC. The resulting data have strengthened the rationale of current experimental therapies for various stages of clinical validation, and have elucidated novel treatment options that are currently under investigation. The overall aim is to improve the effectiveness of current therapeutic regimens and to improve patient quality of life.

Here, we review management strategies for cases of advanced stage GC, current knowledge regarding the molecular classification of GC, and we discuss the emerging role of signaling pathways that are affected in GC and that provide the identification of new therapeutic targets for this disease.

MANAGEMENT OF ADVANCED STAGE GC {#s2}
===============================

The outcome for patients with GC is predicted based on the initial stage of the disease at diagnosis. Localized disease that is limited to the mucosa and submucosa is frequently cured with surgical treatment. The five-year survival rate for these cases is 70-90% \[[@R6], [@R7]\]. However, upon invasion of the sub-mucosa by GC, the risk of lymph node metastases increases and patient survival decreases. Correspondingly, the five-year survival rate following radical gastrectomy without any further treatment is 10-30% \[[@R7], [@R8]\]. Several strategies have been developed to improve overall survival (OS) for cases involving locally advanced disease. The strategies that have achieved some survival benefit compared with surgery alone include adjuvant chemoradiotherapy (CRT), perioperative chemotherapy, and adjuvant chemotherapy.

The adjuvant CRT has been considered standard therapy in the USA since the publication of the phase III Intergroup-0116 (INT 0116). This study included 566 patients who received surgery alone or a CRT regimen of 5-fluorouracil (5-FU) plus leucovorin followed by 4500 cGy radiation. The median OS period for the surgery-only group was 27 months, compared with 36 months for the CRT group. In addition, the hazard ratio (HR) for death was 1.35 (95% confidence interval (CI): 1.09-1.66; *P* = 0.005), and the HR for relapse was 1.52 (95% CI: 1.23-1.86; *P* \< 0.001) \[[@R9]\]. However, this study has been criticized for the limited lymph node dissections performed on the patients enrolled, the complexity of the CRT protocol and for the rate of serious toxicity. Furthermore, there was no evidence for the effectiveness of postoperative adjuvant CRT, and radiotherapy helped only in patients with resected gastric cancer with high-risk loco-regional failure \[[@R10]\]. In contrast to the USA experience, the standard surgery accompanied by D2 lymphadenectomy is performed routinely in Japan. The Korean phase III ARTIST study \[[@R11]\], included 458 GC patients that underwent D2 resection, and were randomly assigned to receive adjuvant capecitabine plus cisplatin (XP), or XP plus radiotherapy (XP/XRT/XP). Overall, the addition of CRT did not benefit GC patients in the chemotherapy alone group, with a 3-year disease-free survival (DFS) rate for the XP/XRT/XP group versus the XP group being 78.2% and 74.2%, respectively (*P* = 0.0862). However, in a subgroup of patients with lymph node-positive disease, the 3-year DFS rates were 77.5% for the XP/XRT/XP group and 72.3% for the XP alone group (*P* = 0.0365).

In the phase III MAGIC trial, 503 patients were enrolled and the benefit of an epirubicine/cisplatin/5-FU (ECF) regimen for perioperative chemotherapy versus surgery alone was demonstrated. The five-year survival rates were 36% versus 23%, respectively (HR = 0.75, 95% CI: 0.60-0.93, *P* = 0.009) and the former group had a higher progression-free survival (PFS) rate (HR = 0.66, 95% CI: 0.53-0.81, *P* \< 0.001). Other potential benefits of this strategy included tumor downstaging, which increased the likelihood of curative resection, improved patient survival with the elimination of micrometastases, a rapid improvement in symptoms, and a determination of tumor sensitivity to chemotherapy \[[@R12]\].

In a meta-analysis conducted by the Global Advanced/Adjuvant *Stomach Tumor* Research International Collaboration (GASTRIC) group \[[@R13]\], 3,838 patients from 17 different trials were examined. A modest, yet statistically significant benefit was observed for the estimated median survival period following the use of post-operative chemotherapy versus surgery alone (7.8 years *vs*. 4.9 years, respectively; HR = 0.82, 95% CI: 0.76-0.90, *P* = 0.001). In the Asian group Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC), S-1, an oral fluoropyrimidine chemotherapy agent, was investigated \[[@R14]\]. In this randomized study of 1,059 patients with stage II-III GC, the 3-year OS rate was 80% versus 70% for surgery alone. Finally, in a capecitabine and oxaliplatin adjuvant study for stomach cancer (CLASSIC), a phase III randomized controlled trial involving 37 centers in South Korea, China, and Taiwan \[[@R15]\], patients with stage II-IIIB GC who underwent curative gastrectomy were randomly assigned to receive adjuvant chemotherapy capecitabine plus intravenous oxaliplatin or surgery alone. The 3-year DFS rates were 74% (95% CI: 69-79) and 59% (95% CI: 53-64), respectively (HR = 0.56, 95% CI: 0.44-0.72; *P* \< 0.0001).

For cases involving advanced, incurable GC, several studies have shown the benefit of palliative chemotherapy. For example, in a meta-analysis of 35 clinical studies and a total of 5,726 patients that was performed to evaluate chemotherapy for cases of advanced stage GC in 2010, a significant benefit in OS was observed for the group that received chemotherapy versus best supportive care (HR = 0.37, 95% CI: 0.24-0.55) \[[@R16]\]. Overall, there has been little progress in the evaluation of new chemotherapy regimens, and the classical regimen of cisplatin plus 5-FU (FP4w) remains the reference regimen. However, there are drugs that have recently been added to third generation regimens, and these include capecitabine, docetaxel, S-1, oxaliplatin, and irinotecan. Pivotal phase III trials suggest that oral XP and S-1 can provide an effective first-line treatment and can replace infused 5-FU \[[@R17]--[@R19]\]. S-1 plus oxaliplatin (SOX) is regarded as a palliative standard first-line chemotherapy in Japan. A phase III study suggested that S-1 plus oxaliplatin (SOX) was non-inferior to cisplatin plus S-1 (CS) in terms of PFS and OS. However, SOX provided a considerable advantage in safety over CS \[[@R20]\]. The regimen FLO (5-FU, leucovorin, oxaliplatin) appeared to reduce the hematological and cardiovascular toxicity and may be an alternative to cisplatin regimen (FLP) for the treatment of advanced GC \[[@R21]\]. Furthermore, the combination of epirubicine, capecitabine, and oxaliplatin (EOX) has been found to be as effective as the ECF regimen \[[@R22]\]. In a phase III study of docetaxel \[[@R23], [@R24]\], and in a study of weekly administrations of paclitaxel and irinotecan \[[@R25], [@R26]\], the potential for these treatments to serve as second-line chemotherapy regimens were evaluated. Selected phase III clinical trials of current chemotherapy regimens for adjuvant and palliative chemotherapy for advanced stage GC are summarized in Table [1](#T1){ref-type="table"}.

###### Pivotal phase III trials using cytotoxic chemotherapy for GC

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Phase III trial                           Patients        Treatment           Clinical efficiency[\*](#tfn_001){ref-type="table-fn"}   Condition                       
  ----------------------------------------- --------------- ------------------- -------------------------------------------------------- --------------- ------ -------- -----------------------------------------------------------------------
  **Adjuvant chemotherapy**                 **Follow-up**   **mRFS (%)**        **Survival rates (%)**                                   ***P-value***                   

  **INT 0116 trial**\                       556             FL                  3 years                                                  31              41     0.005    Resectable GC or GEJ cancer
  **Mcdonald et al. (2001)\[[@R9]\]**                                                                                                                                    

  FL/RT                                                     48                  50                                                                                       

  **ARTIST trial**\                         458             XP                  7 years                                                  74.2            73     NS       Resectable GC with D2 lymph node dissection
  **Lee et al. (2012) \[[@R11]\]**                                                                                                                                       

  XP/XRT/XP                                                 78.2                75                                                                                       

  **MAGIC trial**\                          503             Surgery alone       5 years                                                  18              26     0.009    Resectable GC or GEJ cancer
  **Cunningham et al. (2006) \[[@R12]\]**                                                                                                                                

  Perioperative ECF + surgery                               32                  36.3                                                                                     

  **Asian ACTS-GC trial**\                  1059            Surgery alone       3 years                                                  59.6            70.1   0.003    Resectable GC with D2 lymph node dissection
  **Sakuramoto et al (2007) \[[@R14]\]**                                                                                                                                 

  Surgery + S-1                                             72.2                80.1                                                                                     

  **CLASSIC trial**\                        1035            Surgery alone       5 years                                                  53              69     0.0015   Resectable GC with D2 lymph node dissection
  **Noh et al. (2014) \[[@R15]\]**                                                                                                                                       

  XP                                                        68                  78                                                                                       

  **Palliative chemotherapy**               **ORR (%)**     **mRFS (months)**   **mOS (months)**                                         ***P-value***                   

  **V325 trial**\                           445             DCF                 37                                                       5.6             9.2    0.02     Advanced stage GC and GEJ cancer
  **Ajani et al. (2007) \[[@R24]\]**                                                                                                                                     

  FP4w                                      25              3.7                 8.6                                                                                      

  **ML17032**\                              316             XP                  46                                                       5.6             10.5   0.008    Advanced stage GC
  **Kang et al. (2009) \[[@R18]\]**                                                                                                                                      

  FP3w                                      32              5.0                 9.3                                                                                      

  **SPIRITS trial**\                        305             S-1P                54                                                       6.0             13     0.04     Advanced stage GC
  **Koizumi et al. (2008) \[[@R19]\]**                                                                                                                                   

  S-1                                       31              4.0                 11                                                                                       

  **Yamada et al. (2015) \[[@R20]\]**       685             S-1                 52,2                                                     5,4             13,1   NR       HR: 0.93 Non Inferior

  SOX                                       55,7            5,5                 14,1                                                                                     

  **Al-Batran et al. (2008) \[[@R21]\]**    220             FLO                 35                                                       5.8             10.7   0.08     Metastatic GC and GEJ cancer

  FLP                                       25              3.9                 8.8                                                                                      

  **REAL 2 trial**\                         1002            ECF                 41                                                       6.2             9.9    0.06     Advanced stage GC and GEJ cancer
  **Cunningham et al. (2008) \[[@R22]\]**                                                                                                                                

  ECX                                       46              6.7                 9.9                                                                                      

  EOF                                       42              6.5                 9.3                                                                                      

  EOX                                       48              7.0                 11.2                                                                                     

  **COUGAR-02 trial**\                      168             Docetaxel           53                                                       3.1             5.2    0.01     Refractory treatment fluoropyrimidime plus platinum advanced GC
  **Ford at al. (2014) \[[@R23]\]**                                                                                                                                      

  Symptom control                                           2.0                 3.6                                                                                      

  **French trial**\                         333             IFL                 33                                                       5.0             9.0    NS       Advanced stage and metastatic GC
  **Dank et al. (2008) \[[@R25]\]**                                                                                                                                      

  FP4w                                      26              4.2                 8.7                                                                                      

  **WJOG 4007 trial**\                      223             Paclitaxel          21                                                       3.6             9.5    NS       Refractory treatment fluoropyrimidime plus platinum advanced stage GC
  **Hironaka et al (2013) \[[@R26]\]**                                                                                                                                   

  Irinotecan                                14              2.3                 8.4                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

mRFS: mean relapse-free survival; ORR: overall response rate; mPFS: mean progression-free survival; mOS: mean overall survival; FL: 5-fluorouracil (5-FU), leucovorin; RT: radiotherapy; XP: capecitabine, cisplatin; ECF: epirubicin, cisplatin, 5-FU; DCF: docetaxel, cisplatin, 5-FU; FP4w: 5-FU, cisplatin every 4 weeks; FP3w: 5-FU, cisplatin every 3 weeks; EOX: epirubicin, oxaliplatin, capecitabine; ECX: epirubicin, cisplatin, capecitabine; EOF: epirubicin, oxaliplatin, 5-FU; S-1P: S-1, cisplatin; SOX: S-1 plus oxaliplatin; FLO: 5-FU, leucovorin, oxaliplatin; FLP: 5-FU, leucovorin, cisplatin; IFL: Irinotecan, 5-FU, leucovorin.

The clinical efficacy was calculated from published data.

The first targeted treatment for GC patients that was approved by the Federal Drug Administration (FDA) was trastuzumab in combination with chemotherapy (cisplatin plus either capecitabine or 5-FU). Currently, this treatment regimen is available in the clinic as a first-line therapy for patients with metastatic cancer of the stomach or gastroesophageal junction (GEJ) positive for ERBB2 protein (also called HER2). In the phase III ToGA trial, an increase in OS was observed for patients with ERBB2-positive GC or GEJ that were treated with chemotherapy plus trastuzumab compared to chemotherapy alone \[[@R27]\]. Patients that are diagnosed with metastatic stomach cancer must be evaluated for ERBB2 overexpression or amplification by immunohistochemistry or fluorescence *in situ* hybridization (FISH), respectively. Typically, only 10-30% of these patients are ERBB2-positive and are eligible for treatment with Herceptin plus chemotherapy \[[@R28]--[@R31]\]. Thus, an active area of research is the identification of new molecular therapeutic targets that provide more specific and effective treatments for disease. To understand the impact of using molecular targets for personalized medicine, and why they may be useful in the treatment of GC patients, it is important to describe the histogenetic sequence and the molecular classification of GC that was recently published \[[@R4]\].

MULTISTEP CARCINOGENESIS {#s3}
========================

The majority of GC patients are diagnosed with adenocarcinoma histology (90%); while the remaining 10% of patients are diagnosed with lymphoma or gastrointestinal stromal tumors. In general, there are two types of gastric adenocarcinoma, intestinal-type (50%) and diffuse-type (33%), according to the Lauren classification \[[@R32]\]. The remaining 17% of gastric adenocarcinomas are classified as mixed or are unclassified. Intestinal-type adenocarcinoma is most frequently diagnosed, and it is preceded by the development of gastric lesions known as Correa\'s cascade \[[@R33]\] (Figure [1](#F1){ref-type="fig"}). These lesions have been associated with *H. pylori* infection that possess *cag* pathogenicity island and secrete a functional cytotoxin more severe gastric injury and further augment the risk for developing dismal gastric cancer \[[@R34]\]. In contrast, diffuse-type adenocarcinoma has a poorer prognosis, it generally occurs in younger patients, and it can occur anywhere in the stomach, yet it especially affects the cardia \[[@R35]\].

![Sequential morphologic, genetic and epigenetic alterations in multistep gastric carcinogenesis\
This figure summarizes the sequence of molecular events that have been characterized for intestinal-type and diffuse-type GC according to the Correa cascade model. MSI: microsatellite instability; GS: genomically stable; EBV: Epstein-Barr virus; CIN: chromosomally unstable; LOH: loss of heterozygosity.](oncotarget-06-24750-g001){#F1}

In 1992, Correa proposed that gastric carcinogenesis is a multistep process that involves a sequence of histological changes that lead to intestinal-type adenocarcinoma. These steps include the development of chronic gastritis, atrophy, intestinal metaplasia, and eventually dysplasia that results in GC (Figure [1](#F1){ref-type="fig"}). Recent molecular studies have provided evidence to support Correa\'s model. For example, the initial steps of stomach carcinogenesis have been characterized by genetic instability, telomerase activation, *TP53* loss/mutation, and inactivation of tumor suppressor genes and microRNAs by CpG island methylation \[[@R36]\]. Intestinal metaplasia has been characterized by *TERT* activation, loss of retinoic acid receptor β (*RARB*) expression, *TP53* overexpression, and an abnormal presence of CD44 transcripts. "Gastric adenomas" have been found to exhibit reduced levels of *CDKN1B* expression, overexpression of *CCNE1*, and mutations in the *APC* gene. Furthermore, in cases of advanced stage GC, reduced transforming growth factor β (TGF-β) receptor type I (TβRI) expression and complete loss of function of p27, mutations in tyrosine kinase receptors genes (*EGFR, ERBB2, ERBB3*), amplification of *VEGFA, PIK3CA*, and *KRAS/NRAS*, as well as mutations in chromatin remodeling genes (*ARID1A, MLL3*, and *MLL*) have been observed \[[@R4], [@R6], [@R36]--[@R38]\].

Diffuse-type adenocarcinoma is not associated with *H. pylori* infection and is hypothesized to arise in normal gastric mucosa that contains a greater number of poorly differentiated cells than intestinal-type cells, yet it does not involve a specific carcinogenic sequence. The main molecular changes observed in diffuse-type GCs include microsatellite instability (MSI), loss of E-cadherin function by deletions or mutations in *CDH1*, amplification of *MDM2* and *MET* and *FGFR2F* and *RHOA* mutations \[[@R36], [@R39], [@R40]\]. The main genomic and epigenetic alterations found in intestinal-type and diffuse-type adenocarcinomas are summarized in Figure [1](#F1){ref-type="fig"}. Currently, it remains unclear whether the molecular alterations associated with the Correa carcinogenic model are sequential, or whether some histological changes directly precede GC development \[[@R41]\]. However, an increasing number of genetic abnormalities have been identiﬁed over the past couple decades, thereby providing additional insight into the molecular alterations that lead to the development of GC subtypes.

A NEW MOLECULAR CLASSIFICATION OF GASTRIC ADENOCARCINOMA {#s4}
========================================================

Researchers of the Cancer Genome Atlas Research (TCGA) network recently examined 295 stomach tumors and identified subtypes using complex statistical analyses of molecular data obtained from six molecular analysis platforms that included DNA sequencing, RNA sequencing, and protein arrays. As a result, they have described a new molecular characterization that defines four major genomic subtypes of GC \[[@R4]\]. The most important features and genomic alterations associated with each subtype are shown in Figure [2](#F2){ref-type="fig"}, and these are subsequently discussed in the paragraphs that follow.

![Major features and salient genomic alterations that have been associated with each molecular subtype of GC proposed by the TCGA\
CIMP: CpG island methylator phenotype; EBV: Epstein-Barr virus; MSI: Microsatellite instability; GS: Genomically stable; CIN: Chromosomal instability.](oncotarget-06-24750-g002){#F2}

Epstein Barr Virus (EBV)-positive subtype {#s4_1}
-----------------------------------------

Approximately 9-10% of gastric adenocarcinomas are positive for EBV, and most of these cases involve male patients and the localization of adenocarcinomas in the fundus or body of the stomach \[[@R4], [@R42]\]. EBV is the etiologic agent of infectious mononucleosis and is responsible for certain cancers, including nasopharyngeal carcinoma and some types of lymphoma \[[@R43]--[@R45]\]. In a recent meta-analysis, EBV-associated GC was found to be associated with an infrequent tendency toward lymph node metastasis and a lower mortality rate in different populations \[[@R46]\]. Approximately 80% of EBV-positive tumors harbor mutations in the *PIK3CA* gene \[[@R4]\], which encodes the PI3Kα protein \[[@R47]\]. *PIK3CA* is the second most commonly mutated gene across many cancer types, and was detected in more than 10% of the cancer cases examined by the TCGA \[[@R48]\]. Mutations in *PIK3CA* have been found in 3-42% of the other GC subtypes and in EBV-positive cases. Of particular interest is whether PI3K signaling pathway inhibitors can distinguish EVB-positive versus EBV-negative GC cases. To date, the EBV-positive subgroup of GC cases have showed the highest prevalence of DNA hypermethylation compared with the panel of cancers studied by the TCGA network. Furthermore, promoter hypermethylation of *CDKN2A* has been detected in all EVB-positive samples, and this gene is considered to be one of the most important tumor suppressor genes involved in GC \[[@R49]\]. Amplifications of *JAK2, CD274, PDCD1LG2*, and *ERBB2* have also been detected in EBV-positive GC cases, as well as deletions in *PTEN, SMAD4, CDKN2A*, and *ARID1A*. The JAK/STAT signaling play an important role in proliferation, differentiation and apoptosis and has been intensely investigates in gastric cancer \[[@R50]\] and increased expression of PD-L1 has been correlated with poor prognosis in the GC cases, potentially contributing to immune suppression and evasion \[[@R51], [@R52]\]. Correspondingly, PI3K inhibitors, JAK2 inhibitors, and PD-L1/2 antagonists may have therapeutic value for the treatment of EBV-positive GC patients.

Microsatellite instability (MSI) subtype {#s4_2}
----------------------------------------

MSI is one of the main phenotypes of genomic instability that has been associated with relatively older female GC patients. TCGA researchers have reported that this MSI subgroup represents 21% of the tumors studied, while other groups have reported that MSI cases represent 15-55% of GC cases, depending on the number of loci analyzed \[[@R53]--[@R55]\]. MSI cases are generally characterized by accumulation of mutations in *PIK3CA, ERBB3, ERBB2*, and *EGFR*; along with mutations present in 'hotspot' sites that have been identified in other cancers. Previous studies have reported that the main cause of MSI in GC involves hypermethylation of the *MLH1* promoter, which is one of the genes involved in the DNA mismatch repair system \[[@R4], [@R55]\]. Depending on the level of MSI, GC cases can be categorized as high or low (MSI-H and MSI-L, respectively). Conversely, tumors without instability at any microsatellite loci are categorized as microsatellite stable tumors (MSS) \[[@R56]\]. The MSI-H phenotype has been strongly associated with intestinal-type adenocarcinomas, and is associated with a better prognosis than MSI-L or MSS tumors \[[@R4], [@R55], [@R57], [@R58]\]. MSI has also been hypothesized to play a role in the alteration of genes related to cell cycle control (*TGFBR2, EPHB2, E2F4*), DNA damage repair (*MRE1, ATR*), and apoptotic signaling (*BAX*) \[[@R56], [@R59], [@R60]\].

Genomically stable (GS) subtype {#s4_3}
-------------------------------

The GS subgroup represents approximately 20% of the GC cases examined in the TCGA study \[[@R4]\], and it was enriched with diffuse-type adenocarcinomas. The GS subtype is typically diagnosed in younger patients, it has a rather low frequency of *TP53* mutations, and a low degree of aneuploidy compared with chromosomally unstable GC (described below) \[[@R4]\]. Mutations in the *CDH1* and *RHOA* genes have been detected in 13-37% and in 14-25% of diffuse-type GS adenocarcinoma cases, respectively, thereby highlighting the relevance of altered cell adhesion in the carcinogenesis of this histological type \[[@R4], [@R40], [@R61]\]. *CDH1* germline mutations are associated with hereditary diffuse GC, poorly differentiated phenotype and poor clinical outcome \[[@R62]\]. In contrast, mutated *RHOA* interacts with other cellular proteins to promote morphological changes and cell migration, functions that may be important for tumor growth \[[@R63]--[@R65]\]. Another genetic alteration related to RHOA activity involves the *ARHGAP26* gene, which encodes a GTPase-activating protein that modulates RHOA activation. Interchromosomal translocation between *CLDN18* and *ARHGAP26* has been described, and it is likely that the chimeric product may affect regulation of RHOA. Furthermore, this genomic fusion may also disrupt wild-type *CLDN18*, a tight junction protein that is widely expressed in stomach epithelium and affects cellular adhesion. Interestingly, *CLDN18-ARHGAP26* fusion is mutually exclusive with *RHOA* mutations \[[@R4]\]. Therefore, alterations in the cell adhesion pathways in this GC subtype may facilitate the identification of novel therapeutic targets, particularly those involved in the RHOA pathway.

Chromosomally unstable (CIN) subtype {#s4_4}
------------------------------------

Fifty percent of GC tumors are classified as CIN, and this phenotype is mostly associated with the GEJ/cardia. Moreover, 71% of CIN GC tumors have mutations in *TP53*, followed by mutations in *ARID1A, KRAS, PIK3CA, RNF43, ERBB2*, and *APC* genes. Elevated expression of p53 is consistent with the frequency of *TP53* mutations and aneuploidy that are observed for CIN GC tumors. These findings are also partly consistent with the observation that the highest frequency of loss of heterozygosity occurs at the *APC* (36%) and *TP53* (33%) loci \[[@R4]\]. *TP53* alterations have previously been associated with gastric precancerous lesions; thereby suggesting that loss of p53 function may represent an early event in gastric carcinogenesis \[[@R66]\]. Phosphorylation of epidermal growth factor receptor (EGFR) (pY1068) is also significantly elevated in the CIN subtype, consistent with the detection of *EGFR* amplification in this subtype.

Another important feature of the CIN subtype is the frequent genomic amplification of genes that encode receptors of tyrosine kinases (RTKs), which leads to the promotion of aberrant cell growth. However, the gene that encodes the ligand *VEGFA*, is also frequently amplified in this GC subtype, as demonstrated in studies of ramucirumab, a VEGFR2-targeting antibody. In addition, amplifications of cell cycle mediators (*CCNE1, CCND1*, and *CDK6*) have been observed in the CIN subtype. Many of these genomic amplifications are amenable to blockade by therapeutics that are currently available or are in development, particularly inhibitors of cyclin-dependent kinases.

In the past, GC was considered a single disease. However, it is currently segregated into at least four subtypes according to the spectra of genetic alterations that have been identified. Moreover, these alterations have been associated with relevant clinical features such as etiology, gender, age of diagnosis, and anatomical localization. Taken together, these findings highlight the importance of elucidating the different carcinogenic processes that lead to each subtype, as well as the relevant genes and pathways that may be susceptible to therapeutic targeting.

ONCOGENIC INTRACELLULAR PATHWAYS IN GC AS POTENTIAL THERAPEUTIC TARGETS {#s5}
=======================================================================

By identifying the molecular characteristics of GC, a classification of GC subtypes has been proposed, intracellular pathways that contribute to carcinogenesis have been elucidated, and driver genes have been recognized as potential therapeutic targets. Furthermore, accumulating evidence regarding the molecular abnormalities of GC provide valuable insight into the targets that may be relevant for distinct patient populations, and these remain to be evaluated in clinical trials. In Figure [2](#F2){ref-type="fig"}, the major features and salient genomic alterations associated with each molecular subtype of GC proposed by the TCGA are summarized. In Table [3](#T3){ref-type="table"}, selected clinical trials of novel therapeutic targets for the treatment of advanced stage GC are presented.

###### Signaling pathways and genetic alterations that may represent potential therapeutic targets for GC

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                        Mutation, Amplification and Overexpression Profiling                                                                                                                                    Correlation
  --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  **ErbB Pathway**                                                                                                                                                                                                    

  **EGFR (ERRB1)**            Overexpressed in 9% \[[@R29], \[[@R30]\] and 27.4% \[[@R29]\] of cases\                                                                                                                 Poor prognosis \[[@R29], \[[@R30]\], \[[@R79], \[[@R82]\]
                              Mutated in 5% of cases \[[@R69]\]\                                                                                                                                                      
                              Amplification in 2.3% \[[@R29]\], 5.4% \[[@R69]\], and 8.0% \[[@R67]\] of cases                                                                                                         

  **ERBB2 (HER2)**            Overexpressed in 9% \[[@R28]\], 9.3% \[[@R255]\], 10.5% \[[@R27]\], 10% \[[@R31]\], 13.6% \[[@R30], [@R256], [@R257]\], 23% \[[@R256]\] and 29.5% \[[@R257]\] of cases\                 Poor prognosis \[[@R27], \[[@R257]\]
                              \[[@R69]\]Mutated in 5% \[[@R69]\]\                                                                                                                                                     
                              Amplification 8.2% \[[@R69], \[[@R255]\], 10.5% \[[@R69]\] and 7.2% \[[@R67]\] of cases\                                                                                                
                              Mutated in 10.5% \[[@R69]\] of cases                                                                                                                                                    

  **ERBB3 (HER3)**                                                                                                                                                                                                    

  **ERRB4 (HER4)**            Mutated 9.4% \[[@R69]\] of cases                                                                                                                                                        

  **VEGF Pathway**                                                                                                                                                                                                    

  **VEGFA**                   Overexpressed in 81.5% \[[@R96]\], 54.2% \[[@R97], \[[@R98]\], and 90.1% \[[@R98]\] of cases\                                                                                           Early event \[[@R96]\], tumor size, stage, and lymph node metastases \[[@R97]\]
                              Amplification in 7.0% \[[@R4]\] of cases                                                                                                                                                

  **VEGFC**                   Overexpressed in 55.4% \[[@R100]\], 74.9% \[[@R98]\], and 88.0% \[[@R99]\] of cases                                                                                                     Lymphatic invasion \[[@R99]\]

  **VEGFD**                   Overexpressed in 63.0% \[[@R99]\] of cases                                                                                                                                              Lymphatic invasion \[[@R99]\]

  **PI3K/AKT/mTOR Pathway**                                                                                                                                                                                           

  **PI3KCA**                  Overexpressed in 35% \[[@R108]\], 80% \[[@R110]\], and 38,2% \[[@R109]\] of cases                                                                                                       Lymph node and distant metastases \[[@R108]\]

  **p-AKT**                   Overexpressed in 82% \[[@R110]\], 42% \[[@R109]\], 40% \[[@R112]\], and 68% \[[@R111]\] of cases                                                                                        Chemoresistance \[[@R133]\], lymph node metastases \[[@R109], \[[@R111]\]

  **p-mTOR**                  Overexpressed in 60% of intestinal-type cases, in 64% of diffuse-type cases \[[@R124]\], and in 71.1% \[[@R125]\] and 79.6% \[[@R109]\] of GC cases                                     Early gastric cancer \[[@R124]\]

  **p-P70S6K**                Overexpressed in 59.5% \[[@R258]\] and 45.5% \[[@R109]\] of cases                                                                                                                       

  **HGF/MET Pathway**                                                                                                                                                                                                 

  **HGF**                     Overexpressed in 87.5% \[[@R143]\] and 73.0% \[[@R144]\] of cases                                                                                                                       Associated with intestinal-type GC \[[@R143]\]

  **MET**                     Overexpressed in 42.0% \[[@R145]\], 46.0% \[[@R146]\], 82.0% \[[@R147]\], 26.0% \[[@R148]\], 43.0% \[[@R150]\], 74.0% \[[@R151]\], 71.1% \[[@R149]\], and 73.7% \[[@R152]\] of cases\   Poor prognosis \[[@R149], [@R151], [@R152]\]
                              Amplification in 1.7% \[[@R153]\] and 4% \[[@R67]\] of cases                                                                                                                            

  **Hedgehog Pathway**                                                                                                                                                                                                

  **PTCH**                    Overexpressed in 16.3% \[[@R68]\] and 64.0% \[[@R259]\] of cases                                                                                                                        Poor prognosis \[[@R204]\]

  **SHH**                     Overexpressed in 71.7% \[[@R205]\] and 65.0% \[[@R259]\] of cases                                                                                                                       Poor prognosis \[[@R196], [@R204], [@R205]\], early event \[[@R196]\]

  **SMO**                     Overexpressed in 12.0% \[[@R68]\] of cases                                                                                                                                              

  **IHH**                     Overexpressed in 20.0% \[[@R68]\] of cases                                                                                                                                              

  **GLI1**                    Overexpressed in 69.0% \[[@R259]\] of cases                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Selected clinical trials that used novel therapeutic targets for the treatment of advanced stage GC

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical trial                                               Agent / Phase                                                        No. of Patients (n)   Treatment            Clinical efficiency[\*](#tfn_002){ref-type="table-fn"}   Condition                   
  ------------------------------------------------------------ -------------------------------------------------------------------- --------------------- -------------------- -------------------------------------------------------- ----------- ------ -------- ----------------------------------------------------------------------
  **EGFR/ERBB2 pathway**                                       **ORR (%)**                                                          **mPFS**              **mOS**              ***P*-value**                                                                        

  **ToGA trial**\                                              Trastuzumab, anti-ERBB2 / Phase III                                  594                   X(FU)P               35                                                       5.5         11.1   0.0046   ERBB2-positive advanced stage GC or GEJ cancer
  **Bang et al. (2010) \[[@R27]\]**                                                                                                                                                                                                                                 

  X(FU)P-T                                                     47                                                                   6.7                   13.8                                                                                                      

  **EXPAND trial**\                                            Cetuximab, anti-EGFR / Phase III                                     904                   XP                   30                                                       4.4         24     0.95     Advanced stage unresectable (M0) or metastatic (M1) GC or GEJ cancer
  **Lordick et al. (2013) \[[@R79]\]**                                                                                                                                                                                                                              

  XP-Cet                                                       30                                                                   5.6                   21                                                                                                        

  **REAL3 trial**\                                             Panitumumab, anti-EGFR / Phase III                                   553                   EOX                  42                                                       7.4         11.3   0.013    Untreated, metastatic or locally advanced stage GEJ cancer
  **Wadell et al. (2013) \[[@R82]\]**                                                                                                                                                                                                                               

  EOX-Pan                                                      46                                                                   6.0                   8.8                                                                                                       

  **TyTAN-Asian trial**\                                       Lapatinib, tyrosine kinase inhibitor of EGFR and ERBB2 / Phase III   261                   Paclitaxel           9                                                        4.4         11     NS       ERBB2-amplified advanced stage GC
  **Satoh et al (2014) \[[@R93]\]**                                                                                                                                                                                                                                 

  Paclitaxel-Lap                                               27                                                                   5.4                   8.9                                                                                                       

  **TRIO-013/LOGIC trial**\                                    Lapatinib, tyrosine kinase inhibitor of EGFR and ERBB2 / Phase III   545                   XELOX                40                                                       5.4         10.5   0.35     ERBB2-positive advanced or metastatic cancer and GEJ cancer
  **Hecht et al. (2013) \[[@R94]\]**                                                                                                                                                                                                                                

  XELOX-Lap                                                    53                                                                   6.0                   12.2                                                                                                      

  **HERBIS-1 trial**\                                          Trastuzumab, anti-ERBB2 / Phase II                                   56                    S-1P-T               68                                                       7.8         16     \-       ERBB2-positive advanced stage GC
  **Kurokawa et al. (2014) \[[@R91]\]**                                                                                                                                                                                                                             

  **VEGF pathway**                                                                                                                                                                                                                                                  

  **AVAGAST trial**\                                           Bevacizumab, anti-VEGF / Phase III                                   774                   X(FU)P               37.4                                                     5.3         10.1   0.1002   Untreated, unresectable locally advanced or metastatic GC and GEJ
  **Ohtsu et al. (2011) \[[@R101]\]**                                                                                                                                                                                                                               

  X(FU)P-B                                                     46                                                                   6.7                   12.1                                                                                                      

  **REGARD trial**\                                            Ramucirumab, anti- VEGFR2 / Phase III                                355                   X(FU)P               24                                                       1.3         3.8    0.047    Previously treated advanced stage GC and GEJ cancer
  **Fuchs et al. (2014) \[[@R103]\]**                                                                                                                                                                                                                               

  X(FU)P\                                                      49                                                                   2.1                   5.2                                                                                                       
  Ram                                                                                                                                                                                                                                                               

  **RAINBOW trial**\                                           Ramucizumab, anti- VEGFR2 / Phase III                                665                   Paclitaxel-placebo   16                                                       2.9         7.4    0.017    Previously treated advanced stage GC and GEJ cancer
  **Wilke et al. (2014) \[[@R104]\]**                                                                                                                                                                                                                               

  Paclitaxel-Ram                                               28                                                                   4.4                   9.6                                                                                                       

  **Li J et al. (2013) \[[@R105]\]**                           Apatinib, anti-VEGFR2 / Phase II                                     114                   Placebo              0                                                        1.4         2.5    0.01     Chemotherapy-refractory advanced stage metastatic gastric cancer

  Apatinib                                                     10                                                                   3.7                   4.8                                                                                                       

  **PI3K/AKT/mTOR Pathway**                                                                                                                                                                                                                                         

  **GRANITE -1 trial**\                                        Everolimus, mTORC1 inhibitor / Phase III                             656                   Placebo              2                                                        1.4         4.3    NS       Advanced stage GC
  **Ohtsu et al. (2013) \[[@R127]\]**                                                                                                                                                                                                                               

  Eve                                                          5                                                                    1.7                   5.4                                                                                                       

  **HGF/MET Pathway**                                                                                                                                                                                                                                               

  **NCT00719550-Completed Iveson et al. (2014) \[[@R155]\]**   Rilotumumab, Anti-HGF monoclonal antibody / Phase 1b-II              121                   Placebo plus ECX                                                              4.2                         Unresectable advanced stage or metastatic GC or GEJ cancer

  Ril (15mg/kg)                                                                                                                     5.1                                                                                                                             

  Ril (7.5 mg/kg)                                                                                                                   6.8                                                                                                                             

  ECX-Ril                                                                                                                           5.7                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ORR: overall response rate; mPFS: mean progression-free survival; mOS: mean overall survival; X(FU)P: Capecitabine or 5-FU and cisplatin; T: Trastuzumab; XP: Capecitabine, cisplatin; Cet: Cetuximab; EOX: Epirubicin, oxaliplatin; Pan: Panitumumab; Lap: Lapatinib; XELOX: Capecitabine, oxaliplatin; S-1P-T: S-1, cisplatin, transtuzumab; B: Bevacizumab; Ram: Ramucirumab; Eve: everolimus; FLP: 5-FU, leucovorin, cisplatin; Ril: Rilotumumab; ECX: epirubicin, cisplatin, capecitabine; Onar: Onartuzumab; Tiv: tivantinib.

The clinical efficacy was calculated from published data

ERBB SIGNALING PATHWAYS {#s6}
=======================

There are four ErbB receptors (1-4) and these are members of the RTK superfamily. These receptors localize to the cell surface and have a predominantly regulatory role in nearly every aspect of cell biology. Accordingly, deregulation of these receptors contributes to the development of various cancers, including GC.

EGFR (ERBB1) {#s7}
============

Activation of EGFR (also referred, as ERBB1) has been reported in 9-30% of GC cases \[[@R29], [@R30]\]. This correlates with 2-8% of GC cases, which are characterized by *EGFR* amplification \[[@R67]--[@R69]\] or mutation (5%) \[[@R69]\]. Interestingly, activation of EGFR mainly due to amplification has been observed in 10% of CIN GC cases, while activation of EGFR due to mutations has been observed in 5% of MSI molecular subtypes \[[@R4]\]. In addition, overexpression of EGFR has been associated with advanced stages of GC and an unfavorable prognosis \[[@R29], [@R30]\]. Binding of different ligands to EGFR, including epidermal growth factor (EGF) and TGF-α, initiates signal transduction cascades that can lead to activation of the mitogen-activated kinase (MAPK) signaling pathway (KRAS/NRAS/RAF/MEK/ERK) and/or the phosphoinositide 3-kinase (PI3K) signaling pathway (PI3K/PTEN/AKT/mTOR). Consequently, EGFR plays a critical role in cell proliferation, differentiation, migration, and survival \[[@R69], [@R70]\]. Interestingly, RTK-RAS has been reported to be a dominant oncogenic pathway in approximately 40% of GC cases, and genes related with this signaling pathway are mutually to one another in GC \[[@R67]\]. The latter include *EGFR*, *ERBB2*, *KRAS*, *FGFR2*, and *MET,* and these genes are frequently amplified in CIN molecular subtype cases of GC \[[@R4]\].

Different strategies have been developed for the targeting of EGFR (Table [3](#T3){ref-type="table"}), including small molecule tyrosine kinase inhibitors and monoclonal antibodies. Regarding the former, antitumor activity was observed in patients with distal esophageal and GEJ adenocarcinomas that were treated with erlotinib, but the same activity was not observed in patients with distal gastric tumors \[[@R71]\]. In other studies, treatment with gefitinib demonstrated biologic activity against EGFR, yet a comparable response and OS rate was observed for the treatment with gefitinib or erlotinib \[[@R72], [@R73]\].

Of the studies performed for EGFR-targeting monoclonal antibodies, three recombinant antibodies have been evaluated in clinical trials. Cetuximab is a recombinant human/mouse chimeric monoclonal antibody against EGFR and it represents the best-characterized anti-EGFR therapy for GC to date. In a phase II study that evaluated the use of cetuximab as a single agent for the treatment of patients with metastatic GC, minimal clinical activity was observed, and this was characterized by a response rate of 3%, a stable disease rate of 6%, and a median survival period of 3.1 months \[[@R74]\]. In contrast, when cetuximab was used as a first-line treatment in combination with various chemotherapy regimens in several phase II studies, a tendency for improvement in treatment response was observed in a subset of GC patients, with the overall response rates varying from 40-60% \[[@R75]--[@R78]\]. However, in the EXPAND trial \[[@R79]\], an open-label, randomized phase III trial that assessed the combination of cetuximab with XP chemotherapy for patients with advanced stage gastric or GEJ cancer, the median PFS period was 4.4 months (*n* = 455, 95% CI: 4.2-5.5) compared with 5.6 months (*n* = 449, 95% CI: 5.1-5.7) for the patients who received XC chemotherapy alone (*p* = 0.32). Thus, the addition of cetuximab to XP chemotherapy did not provide additional benefit to chemotherapy alone for the first-line treatment of advanced stage GC patients.

Matuzumab and panitumumab are two other anti-EGFR monoclonal antibodies that have been evaluated in clinical trials. Matuzumab first emerged as a promising drug based on the results of a phase I study for the treatment of patients with solid tumors \[[@R80]\]. However, the efficacy of matuzumab for GC has not been demonstrated. In a recent phase I clinical trial conducted by Trarbach et al., the use of matuzumab in combination with 5-FU, leucovorin, and cisplatin for the treatment of advanced stage GC patients was investigated. Matuzumab demonstrated an acceptable safety profile with modest anti-tumor activity, yet the confirmed overall response rate was low (26.7%) \[[@R81]\]. Similar findings were reported for panitumumab in the REAL3 trial, a randomized multicenter phase III study where the clinical efficacy of an epirubicin, oxaliplatin, and capecitabine (EOX) regimen with or without panitumumab was evaluated for the treatment of previously untreated advanced esophagogastric cancer. The addition of panitumumab significantly reduced the median OS period from 11.3 months for the patients that received EOX (95% CI: 9.6-13.0) to 8.8 months (95% CI: 7.7-9.8) for the patients that received panitumumab plus chemotherapy. Furthermore, EOX plus panitumumab was associated with increased grade 3 and 4 adverse effects, requiring dose reductions. The anti-EGFR phase III trials EXPAND and REAL-3, for cetuximab and panitumumab respectively, failed to meet their primary endpoints, casting a large shadow over future prospects for other anti-EGFR drugs \[[@R83]\]. However, in both trials EGFR-overexpressing patients were not preselected as an inclusion criterion in the trial, and later subgroup analyses may be effective in the subgroup of patients that highly express EGFR \[[@R79]\]. Another important aspect to highlight in the failure of anti-EGFR targeted therapy are the intra-tumor heterogeneity, acquired resistance to anti-EGFR inhibitors and the non-existence of an established biomarker to predict response to anti-EGFR treatments \[[@R84], [@R85]\]. Acquired resistance to anti-EGFR inhibitors may result from activation of partner of HER family (HER3 and/or HER2), which share overlapping signaling pathways \[[@R86]\]. In colon cancer studies, *RAS* mutations (*KRAS* and *NRAS*) have been investigated as predictive markers of anti-EGFR treatments. In contrast, RAS mutation is only observed in 5% of GC patients \[[@R87]\], and there has been no definite evidence of its mutation playing a role as a predictive factor for anti-EGFR antibody therapy.

Taken together, these finding suggest that an EGFR-targeting agent alone is not effective in all patients with GC and there may be a preferred chemotherapy partner for the EGFR antibody \[[@R86]\]. Furthermore, additional clinical trials should assess the activity of EGFR-targeting inhibitors according to the different molecular subgroups of advanced stage GC, including subtyping for EGFR amplification.

ERBB2 (HER2) {#s8}
============

Overexpression of ERBB2 (which is also commonly referred to as HER2) has been detected in 10-30% of GC cases, with amplification of *ERBB2* detected in 2-27% of GC cases \[[@R28]--[@R30]\] and *ERBB2* mutations detected in 5% of GC cases \[[@R69]\]. Overexpression of ERBB2 has also been associated with *ERBB2* amplification in 24% of CIN GC cases and in 12% of EBV cases, while *ERBB2* mutations have been detected in 7% of MSI molecular subtypes \[[@R4]\]. Moreover, overexpression of ERBB2 has been associated with poor prognosis and more aggressiveness disease \[[@R28]\].

To date, targeting of ERBB2-overexpressing tumors with trastuzumab has been the most successful example of a targeted agent used for the treatment of GC \[[@R88]\]. Trastuzumab is a recombinant humanized monoclonal antibody that is designed to target and block ERBB2 by inhibiting dimerization, by inducing antibody-dependent cellular cytotoxicity, and by increasing receptor endocytosis \[[@R89], [@R90]\]. Trastuzumab was the first drug successfully used to treat ERBB2-amplified, advanced stage GC as demonstrated in the Trastuzumab for Gastric Cancer (ToGA) trial \[[@R27]\]. In this phase III multicenter, randomized controlled study, the efficacy of two first-line chemotherapy regimens consisting of trastuzumab combined with standard chemotherapy (XC or 5-FU plus cisplatin) versus the use of chemotherapy alone was examined for patients with inoperable, locally advanced, recurrent or metastatic ERBB2-positive gastric cancer. Patients in the trastuzumab group had a longer OS period than those who received chemotherapy alone (13.8 months *vs*. 11.1 months, respectively). Treatment with trastuzumab also improved the median PFS period (6.7 months *vs*. 5.5 months, respectively) and the radiological response rate (47% *vs*. 35%, respectively). Similar results were obtained in a Phase II study that evaluated the use of trastuzumab in combination with cisplatin in patients with untreated ERBB2-positive advanced gastric or gastroesophageal junction cancer \[[@R31]\]. In a recent phase III trial that combined the use of trastuzumab with S-1 plus cisplatin, a response rate of 68% (95% CI: 84-94%) and median OS and PFS periods of 16.0 months and 7.8 months, respectively \[[@R91]\]. Taken together, these results suggest that trastuzumab represents a new therapeutic option for patients with ERBB2-positive advanced stage GC. To further investigate the role of other ErbB receptors, a phase I trial is recruiting patients to evaluate a treatment regimen including trastuzumab and LJM716, a ERBB3 protein inhibitor (NCT01602406) \[[@R92]\]. ERBB3 appears to be activated by mutations in 14% of MSI GC cases, while amplifications of ERBB3 have been detected in 8% of CIN molecular subtypes of GC \[[@R4], [@R69]\].

Another drug that was recently described with positive results against ERBB2-positive GC is lapatinib, an intracellular tyrosine kinase inhibitor of EGFR and ERBB2 that acts by blocking autophosphorylation and downstream signaling. The combination of lapatinib with paclitaxel showed anti-tumor activity as a second-line treatment for patients with ERBB2 FISH-positive IHC 3+ advanced stage GC, yet it did not significantly improve the OS of the intent-to-treat population \[[@R93]\]. In the TRIO-013/LOGIC trial, a first-line treatment for ERBB2 overexpression due to gene amplification, advanced stage GC patients was evaluated with lapatinib combined with capecitabine and oxaliplatin (e.g., the XELOX regimen) in 545 patients. PFS, but not OS, was found to be improved \[[@R94]\]. The non-survival benefit shown by Lapatinib combination therapies has been correlated with serious adverse effects such as diarrhea and skin toxicity \[[@R93], [@R94]\]. Currently, a phase I clinical trial to evaluate the combination the lapatinib with trastuzumab in locally advanced or metastatic GC is in the process of being reported (NCT01705340) \[[@R92]\].

Currently, ERBB2-positive patients with advanced stage GC receive a standard therapy of capecitabine or 5-FU with cisplatin and trastuzumab. To date, the role of lapatinib, alone or in combination with trastuzumab, appears to be promissory, although additional clinical trials are necessary. An accurate molecular characterization of ERBB2-positive tumors is also necessary in order to define which patient groups are likely to benefit from a targeted therapy, thereby improving the cost-effectiveness and efficacy of GC treatment.

THE VEGF PATHWAY {#s9}
================

Angiogenesis is defined as the formation of new blood vessels from pre-existing vasculature and is considered a hallmark of cancer. Angiogenesis also involves the proliferation and migration of endothelial cells into nutrient-deprived tissues, especially into regions adjacent to a tumor where the formation of patent blood vessels is initiated \[[@R95]\].

VEGFA is a member of the PDGF/VEGF growth factor family and it encodes a protein that is often found as a disulfide-linked homodimer. VEGFA acts specifically on endothelial cells and mediates various effects, including increased vascular permeability, angiogenesis, vasculogenesis, and endothelial cell growth, thereby promoting cell migration and inhibiting apoptosis. VEGFA overexpression has been reported in 54-90% of GC cases, and has been described as an early marker in the development of GC \[[@R96]--[@R98]\]. Furthermore, expression of VEGFA has been found to correlate with lymph node metastasis and poor prognosis. The growth factors, VEGFC and VEGFD, are also overexpressed in 50-80% of GC cases, and high levels of expression correlate with lymphatic invasion \[[@R99], [@R100]\]. Interestingly, recurrent amplification of VEGFA has recently been reported to be a trait of the CIN subtype of GC, and this subgroup of cases may be candidates for VEGF-targeting therapies \[[@R4]\].

Anti-angiogenesis therapies have been well-studied for cases of advanced stage GC (Table [3](#T3){ref-type="table"}). For example, in the multinational, placebo-controlled phase III trial, Avastin in Gastric Cancer (AVAGAST), the efficacy of adding bevacizumab to a XP protocol for the first-line treatment of advanced stage GC was examined. Unfortunately, AVAGAST did not accomplish its primary endpoint of extending the OS of patients with GC \[[@R101]\]. However, subgroup analyses demonstrated that significantly longer OS periods were achieved for patients from non-Asian regions \[[@R17], [@R102]\]. Ramucirumab, a monoclonal VEGFR2 antagonist, is the first FDA-approved biological therapy for the treatment of advanced stage GC that is unresponsive to fluoropyrimidine or platinum-containing chemotherapy. In a phase III trial where remucirumab was administered as a single drug for patients with advanced stage GC, the OS period for the patients that received ramucirumab versus a placebo was 5.2 months and 3.8 months, respectively (*P* = 0.047) \[[@R103]\]. Furthermore, in the RAINBOW trial, paclitaxel plus ramucirumab versus paclitaxel plus placebo were compared for the treatment of advanced, pretreated cases of GC. The results of this trial confirmed the survival advantage of ramucirumab plus paclitaxel for the treatment of GC in non-Asian population \[[@R104]\]. The absence of survival benefit in the RAINBOW and AVAGAST in the Asian patient subset could be explained by the overall survival in patients from Asia being extremely longer than non-Asian patients, independent of treatment. It was difficult to obtain the survival benefit in Asian patients with good performance status and subsequent therapies compared with the rest of the world. Moreover, the differences between Asian and Western patients could have affected the results, for example the proportion of different subtypes of molecular groups, the proportion of GC related to EBV, the expression of polymorphism of interleukin or the expression of distinct tumor immunity signatures related to T-cell function.

Others agents that have recently been evaluated in phase II trials include apatinib, a VEGFR2 inhibitor, and the multi-targeted tyrosine kinase receptor inhibitor, sorafenib. For cases involving chemotherapy-refractory advanced stage metastatic GC, treatment with apatinib improved the OS and PFS of this cohort \[[@R105]\]. In a previous study, sorafenib treatment combined with chemotherapy resulted in a median OS period of 13.6 months and a median PFS period of 5.8 months in patients with metastatic or advanced stage GC and GEJ cancer \[[@R106]\]. Based on these results, additional studies of these inhibitors in combination with chemotherapy are required.

THE PI3K / AKT / MTOR SIGNALING PATHWAY {#s10}
=======================================

The PI3K family of intracellular kinases mediates the regulation of cell survival, proliferation, differentiation, migration, and metabolism \[[@R107]\]. In particular, subunit p110α of PI3K is downstream of activated RTKs, such as EGFR and ERBB2, is an activator of AKT, and is also a downstream effector of the mammalian target of the rapamycin (mTOR) pathway (Figure [3](#F3){ref-type="fig"}). Activation of the PI3K/AKT/mTOR pathway can be triggered by the activation of RTKs, *PI3KCA*-activating mutations and amplifications, loss of *PTEN* function due to deletions or mutations, and overexpression or activating mutations of *AKT1*.

![Pathways that represent potential targets for the treatment of advanced stage GC\
The components of each signaling pathway are colored according to their dominant alteration type (see key at lower left). Targeted agents (listed in yellow boxes) include those in clinical use (colored in green) and those in preclinical or early phase development (colored in red) for the treatment of advanced stage GC. BCL2, associated agonist of cell death; EGFR, epidermal growth factor receptor; NICD, NOTCH intracellular domain; PTCH, Patched; SMO, Smoothened; SSH, slingshot.](oncotarget-06-24750-g003){#F3}

The PI3K/AKT/mTOR pathway is frequently activated in GC, with overexpression of *PI3KCA* described in 35-80% of GC cases \[[@R108]--[@R110]\], and phosphorylation of AKT described in 40-82% of GC cases \[[@R109]--[@R112]\]. Expression of PI3KCA and phosphorylated AKT has also been associated with lymph node metastasis \[[@R108], [@R109], [@R111]\]. Furthermore, alterations in *PIK3CA* have been detected in 80% and 42% of the EBV and MSI molecular subtypes of GC, respectively \[[@R4]\].

To date, two classes of PI3K inhibitors have been evaluated for the treatment of GC: pan-PI3K inhibitors, which target all PI3K family members (BKM120, PX-886, and XL147), and isoform-specific PI3K inhibitors, which specifically target the p110 catalytic subunit of PI3K (BYL719, GDC0032, and INK1117) \[[@R113]\]. In particular, the pan-PI3K inhibitor, BKM120, has been evaluated in solid tumors, including GC tumors, in combination with LDE225, a hedgehog pathway inhibitor (NCT0157666) \[[@R92]\]. Currently, the isoform-speciﬁc p110α inhibitor, BYL719, and the heat shock protein 90 inhibitor, AUY922, are being evaluated in a phase I trial with advanced stage GC patients that carry either a molecular alteration of PIK3CA, or *ERBB2* ampliﬁcation (NCT01613950) \[[@R92]\]. Due to the structural similarity of the catalytic domains of p110 and mTOR, dual PI3K/mTOR inhibitors (BEZ235, XL765, GDC-0980, GDC0084, SF1126, and PF-46915) have also been developed \[[@R114]\]. These dual PI3K/mTOR inhibitors have been shown to enhance 5-FU cytotoxicity both *in vitro* and *in vivo* \[[@R115]\], especially in PI3KCA mutant gastric tumor cells which are thought to be secondary to cellular heterogeneity in regard to sensitivity to PI3K and mTOR inhibition \[[@R116]\].

Two types of AKT inhibitors been evaluated in clinical trials: allosteric inhibitors (MK-2206) and catalytic site inhibitors (AZD5363, GSK690693, and GDC0068). The allosteric inhibitors of AKT, have been effective against breast cancer cell lines carrying *PI3KCA* mutations and *ERBB2* ampliﬁcations \[[@R117]\]. Currently, MK2206 is being studied in early phase trials in mutation-selected and unselected patients with advanced stage gastric or GEJ cancers or other solid tumors (NCT01260701) \[[@R92]\]. Of the catalytic site inhibitors, AZD5363 has shown activity against GC cell lines *in vitro* \[[@R118], [@R119]\], and, as a monotherapy, has mediated partial responses in two patients that harbored tumor mutations in either *AKT1* or *PI3KCA* \[[@R120]\]. Similarly, GDC0068 has exhibited anti-tumor activity in human cancer cell lines and xenograft models \[[@R121]\], and is being investigated in a multicenter phase II trial of gastric and GEJ cancer patients with locally advanced or metastatic disease (NCT01896531) \[[@R92]\].

The mTOR complex-1 (mTORC1) inhibitor, everolimus, has been used to successfully treat several cancer types \[[@R122], [@R123]\]. For GC, everolimus has been tested in phase II and III clinical trials of advanced stage and metastatic GC patients, since activation of mTOR has been reported to occur in 60-80% of GC cases \[[@R109], [@R124], [@R125]\]. In a recent phase II trial, everolimus demonstrated a response rate of 3.7% (2/44) and a disease control rate (DCR) of 38.9% (17/44) \[[@R126]\]. However, in a phase III GRANITE-1 study which evaluated the efﬁcacy of everolimus compared to the best supportive care available for molecularly unselected patients with advanced stage GC that progressed after previous chemotherapy, improved survival was not significantly observed (5.39 months with everolimus versus 4.34 months with placebo, HR, 0.90; 95% CI: 0.75 - 1.08; *P* = 0.124) \[[@R127]\]. It is possible that since everolimus only suppresses mTORC1, feedback activation of MAPK may limit the anti-tumor potency of everolimus \[[@R128]\]. Correspondingly, there are a few inhibitors that target both mTORC1 and mTORC2 that have exhibited improved potency (OSI-027, BEZ235, XL765, AZ8055, Ink128) and are currently being evaluated in phase I/II trials for patients with other types of solid tumors.

The molecular mechanisms involved in sensitivity to PI3K inhibitors are yet to be clarified in order to translate preclinical activity into clinical benefit, and to date the development of PI3K inhibitors in advanced GC is still in the preclinical stage \[[@R129]\]. Junk et al. \[[@R130]\] observed that 78% of patients with colorectal cancer with the *PIK3CA* mutation also had simultaneous *KRAS* mutation and did not respond to PI3K/AKT/mTOR axis therapy. By contrast, patients with ovarian cancer and simultaneously occurring *KRAS* or *BRAF* mutations achieved a partial response with these inhibitors, thereby indicating that the RAS/RAF/MEK pathway serves as a driver of resistance to PI3K inhibitors and suggesting that screening for *PI3KCA* (and *RAS* or *RAF*) could be used to predict PI3K/AKT/mTOR response clinically. In gastric cancer, the PIK3CA mutation is an important biomarker for predicting the treatment response of everolimus and AKT inhibitors \[[@R118], [@R131]\]. In contrast, the predictive ability of *KRAS* and *BRAF* mutations has not been extensively studied, but a few reports have demonstrated that the frequency of these concurrent aberrations is very low \[[@R87], [@R118]\]. Moreover, several studies have implicated the PI3K/AKT/mTOR pathway in mediating resistance by GCs to chemotherapy and anti-ERBB2 treatment \[[@R132]--[@R134]\]. It is hypothesized that AKT affects the BCL2 protein and the NF-κB pathway, although PI3K may also induce upregulation of the chemo-resistance proteins, MDR1/Pgp, BCL2, and XIAP, while downregulating the expression of BAX and caspase 3. In tumor tissues from GC patients that were examined *in vitro*, AKT activation and *PTEN* loss were associated with increased resistance to multiple chemotherapeutic agents (5-FU, doxorubicin, mitomycin C, and cisplatin) \[[@R135]\]. Similarly, a combination of PI3K and AKT inhibitors with chemotherapy agents has successfully attenuated chemotherapeutic resistance in a synergistic manner in GC cell lines \[[@R134], [@R136]\] and other cancer models \[[@R121]\], especially those characterized by *PTEN* loss \[[@R118]\]. A similar association was observed following activation of the PI3K/AKT pathway and resistance to anti-ERBB2 agents in other cancers \[[@R118], [@R119]\]. Based on the observation that *PTEN* loss was detected in a majority of ERBB2-positive GC cases \[[@R137]\], it is possible that *PTEN* loss explains the observed clinical resistance of ERBB2-positive GC patients to current anti-ERBB2 therapies.

THE HGF/MET SIGNALING PATHWAY {#s11}
=============================

This pathway is characterized by the joint action of two proteins: hepatocyte growth factor (HGF) (also referred to as scatter factor) and its only known receptor, MET. These proteins regulate multiple cellular processes that stimulate cell proliferation, migration, invasion, angiogenesis, apoptosis, and metastasis, thereby leading to the activation of MAPK, PI3K-AKT, v-src sarcoma viral oncogene homolog, and signal transducer and activator of transcription (STAT) signaling pathways \[[@R138]--[@R140]\]. Recent evidence has also highlighted the additional roles for the MET in cancer via crosstalk with other receptors and cell surface proteins, such as *TGFB1* and *EGFR* \[[@R141]\], and these interactions contribute to oncogenesis and drug resistance \[[@R142]\].

Overexpression of HGF and MET \[[@R143], [@R144]\] have been reported in 73-88% and 26-82% \[[@R145]--[@R152]\] of advanced stage GC cases, respectively. Furthermore, overexpression of MET has been associated with poor prognosis in advanced stage GC cases \[[@R149], [@R151], [@R152]\]. Inappropriate MET signaling in cells can be triggered by several mechanisms. The first is related to a *MET* rearrangement generated by chromosomal translocation and fusion of a TPR (translocated promoter region) locus on chromosome 1 to the 5′region of sequences derived from the *MET* locus on chromosome 7. This genomic rearrangement results in activation of MET via dimerization of its kinase domain and allows MET to escape the normal mechanisms of down-regulation. The *TPR-MET* chromosomal translocation has been found in precursor lesions of GC and in adjacent normal mucosa \[[@R139]\]. Other genetic mechanisms that could be related to GC lesions include gene amplifications, gene mutations, and transcriptional up-regulation of *MET* and/or *HGF* genes. Correspondingly, *MET* gene amplification with consequent protein overexpression and constitutive kinase activation has been reported in 2-4% \[[@R67], [@R153]\] of advanced stage GC cases, amplifications of *MET* have been detected in 8% of CIN GC lesions, and *MET* mutations are present in approximately 3% of MSI subtype GCs \[[@R4]\].

MET is a popular target and several clinical trials are underway to evaluate monoclonal antibodies, such as rilotumumab (AMG102), onartuzumab (MetMAb), ABT-700 as well as MET-specific and multi-targeted small-molecule tyrosine-kinase inhibitors, for the treatment of GC. Specifically for the treatment of GEJ and GC in the later stages of clinical development, the monoclonal antibodies, tivantinib, AMG 337, foretinib, cabozantinib, and golvatinib, are also being investigated \[[@R139]\].

Rilotumumab is a neutralizing monoclonal antibody that prevents the binding of HGF/SF to the MET receptor and its subsequent signaling \[[@R154]\]. In a phase II study of rilotumumab in combination with epirubicin, cisplatin, and capecitabine (ECX) for the treatment of advanced stage or metastatic gastric and GEJ cancers, an improvement in OS and PFS was observed for the patients that received rilotumumab plus ECX \[[@R155]\]. It is hypothesized that high MET expression detected by immunohistochemistry may predict a clinical benefit from rilotumumab plus ECX for GC patients, and may also be associated with a poor prognosis for ECX-treated patients. These possibilities are being addressed in the terminated RILOMET-1 phase III trial that includes MET-positive GC and GEJ patients (NCT01697072) and the final results are expected to be published \[[@R92]\]. Onartuzumab (MetMAb) is an *Escherichia coli*-derived, humanized monovalent (one-armed), monoclonal antibody against MET \[[@R156]\]. In contrast, the monovalent design of onartuzumab inhibits HGF/SF binding without inducing MET dimerization \[[@R157]\]. When onartuzumab was administered by intravenous infusion as a single agent or in combination with bevacizumab in patients with advanced solid malignancies as part of a phase I study \[[@R158]\], promising results were obtained. Therefore, onartuzumab has been advanced to phase II and III studies in combination with FOLFOX to treat patients with metastatic ERBB2-negative solid tumors, including GC. The results of these studies are expected soon (NCT01590719 and NCT01662869) \[[@R92]\]. Another important monoclonal antibody is ABT-700, which has shown promising anti-tumor activity in patients with *MET* amplification solid tumors \[[@R159]\]. The ABT-700 was well tolerated at the recommended single-agent dose of 15mg/kg without important adverse events. Furthermore, a phase I study using ABT-700 monotherapy showed a 50% response rate in patients with *MET*-amplified advanced gastric and esophageal cancer (NCT01472016) \[[@R160]\]. Interestingly, the *MET* amplification appears to be more common in metastatic recurrent tumors than in primary tumors and this highlights the importance of identifying *MET* amplification as a predictive biomarker of clinical benefit in a treatment-refractory patient population.

To date, only a few MET inhibitors have undergone clinical trials. Tivantinib is a small molecule that represents an orally bioavailable MET inhibitor that blocks the MET receptor in its non-phosphorylated, inactive conformation and interrupts downstream signaling \[[@R161]\]. In a recent phase II trial for tivantinib, modest efficacy was observed in an Asian patient that was previously treated for metastatic GC \[[@R162]\]. Currently, a phase I-II trial is being conducted to evaluate combinations of tivantinib and FOLFOX, pazopanib, and bevacizumab for the treatment of patients with GEJ and gastric cancer (NCT01611857, NCT01468922 and NCT01749384) \[[@R92]\]. The novel AMG 337 MET tyrosine-kinase inhibitor looks promising and points towards a potentially effective new treatment option for a new patient subgroup with MET-amplified gastric, esophageal and GEJ tumors \[[@R163]\]. In a phase I analysis of AMG 337 monotherapy, 14.4 % (13/90) of patients showed *MET* amplification. Among these 13 patients, 62% (8/13), achieved an objective response to AMG 337. The daily maximum tolerated dose was 300 mg and in regard to safety the most common adverse events were nausea, vomiting and fatigue, and the only dose-limiting toxicity was headache \[[@R164]\]. On the basis of these results, a phase II study is currently recruiting patients (NCT02016534) \[[@R92]\]. In addition, foretinib (GSK1363089, XL880), an oral multikinase that primarily targets MET, RON, AXL, and VEGFR, is also being investigated \[[@R165]\]. In preclinical studies, foretinib prevented tumor growth by mediating a direct effect on cell proliferation and by inhibiting cell invasion and angiogenesis that involved the HGF and VEGF receptors \[[@R166]\]. In a phase II trial of metastatic GC patients, administration of foretinib alone did not provide sufficient efficacy in unselected patients with metastatic GC and this absent of response could be due to the evaluation of non-molecularly selected population \[[@R167]\]. Other tyrosine kinase inhibitors that have been examined include cabozantinib (XL184) and golvatinib (E7050). The former is a multikinase inhibitor that targets MET, VEGFR2, AXL, Tie2, KIT, FLT3, and RET \[[@R168]\]. In 2012, the FDA approved cabozantinib for the treatment of patients with metastatic medullary thyroid cancer, and a phase II clinical trial for the treatment of advanced stage malignancies by cabozantinib, including gastric and GEJ cancer, is ongoing (NCT00940225) \[[@R92]\]. Golvatinib (E7050) is an ATP-competitive inhibitor of MET receptors that potently and selectively inhibits the autophosphorylation of MET and VEGF-induced phosphorylation of VEGFR. When golvatinib in combination with gefitinib was used to treat EGFR-mutated lung cancer cell lines, the MET/Gab1/PI3K/AKT pathway was blocked \[[@R169]\]. Golvatinib was subsequently evaluated in a phase I study in patients with advanced stage solid tumors \[[@R170]\]. Currently, studies of golvatinib (E7050) in combination with other targeted agents, including sorafenib, and with lenvatinib (E7080) in patients with advanced stage malignancies, are ongoing. These results, as well as those of ongoing studies, are of great interest regarding this promising pathway in GC.

THE RHOA SIGNALING PATHWAY {#s12}
==========================

Rho GTPases are important intracellular signaling molecules that regulate cytoskeleton organization, cell cycle, and cell motility, among other processes. In cancer, Rho activity promotes metastasis by disrupting the epithelial layer, by fostering motility, and by inducing degradation of the extracellular matrix \[[@R171]\]. In recent studies, well-described *CDH1* mutations, as well as *RHOA* mutations, have been found to be strongly related to histologic diffuse-type gastric carcinogenesis \[[@R40], [@R61]\], and this in turn, enriches the GS subgroup of GC \[[@R4]\]. These results are consistent with the hypothesis that diffuse-type GC is a neoplasm whose initial existence relies more on the inherent characteristics of the tissue than on disorganization of the genome, compared with the other subtypes \[[@R62]\]. The diffuse-type subtype is also characterized by the early breaking-off of signet-ring cells through the basement membrane, and this process requires resistance to anoikis (e.g., apoptosis induced by a lack of correct cells to extracellular membrane attachment) and is characterized by an infiltrative phenotype. In three-dimensional cultures, mutated *RHOA* has been associated with an ability to promote escape from anoikis and to facilitate tumor growth, thereby implicating RHOA as an oncogenic driver of diffuse-type GC progression \[[@R40], [@R61]\]. Rhosin and Y16 represent newly developed Rho-specific inhibitors that potently suppress breast cancer cell proliferation, migration, and invasion *in vitro* \[[@R172]\]. However, due to their distinct mechanisms, they are able to act synergistically to inhibit RHOA-mediated cell stress fiber formation \[[@R172]--[@R174]\]. Ripasudil, a selective inhibitor of Rho-associated coiled coil-containing protein kinase (ROCK) was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension \[[@R173]\]. Accordingly, it is predicted that current and future drugs that inhibit the RhoA pathway will be evaluated in clinical trials in patients with GC.

THE JAK/STAT SIGNALING PATHWAY {#s13}
==============================

Janus-associated kinase 2 (*JAK2*) is overexpressed in a subset of EBV-subtype GCs, and the JAK/STAT signaling pathway has been detected in several types of tumors, including GC \[[@R50], [@R175]\]. Therefore, JAK2 inhibitors may also represent a potential therapeutic treatment for GC. JAK2 is potentially the most influential kinase in this family based on its interactions with growth hormone receptors and cytokine receptors. Following the activation of JAK2 by phosphorylation, STAT phosphorylation is induced and gene expression involved in cell proliferation and apoptosis arrest is stimulated \[[@R176]\]. Inhibition of JAK2 has been applied to myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis \[[@R177]\]. For multiple myeloma patients, inhibition of JAK2 led to a significant reduction in splenomegaly, an elimination of debilitating disease-related symptoms, and weight gain \[[@R178]\]. JAK2 inhibiting drugs include: INCB018424 (phase III), TG101348 (phase II), and CEP701 (phase I/II) \[[@R178], [@R179]\]. Other JAK2-inhibiting molecules have been investigated as well. For example, AZD1480 was tested in a phase I study of 38 patients with advanced stage solid tumors, and rapid absorption and elimination of this drug was observed (NCT01219543) \[[@R92]\]. However, the authors could not establish whether dose-limiting toxicities were due to inhibition of JAK1/2 or were due to off-target effects \[[@R180]\]. AG-490 has been tested on SGC7901 and AGS gastric cell lines, and inactivation of JAK2 and induction of apoptosis were observed in the latter \[[@R181]\]. Finally, WP-1066 was assessed in AGS cell lines and in gp^757FF^ mice as models of GC. In both models, cell proliferation was blocked, inflammation was reduced, and apoptosis was induced in gastric tumor cells by inhibiting STAT3 phosphorylation. While clinical studies are needed to confirm these promising results in patients with advanced stage GC, WP1066 may form the basis for the development of future therapeutics against GC \[[@R182]\].

STEM CELL PATHWAYS PROVIDE NOVEL GASTRIC CANCER THERAPY TARGETS {#s14}
===============================================================

Gastric cancer stem cells (GCSCs) have been identified in GC cell lines and primary GC tissues \[[@R183]--[@R186]\]. Moreover, recent investigations have shown that gastric GCSCs are a crucial target for GC treatments \[[@R187]--[@R189]\], with strategies targeting self-renewal pathways leading to the direct elimination of cancer stem cells (CSCs). Stemness-related signaling pathways include Hedgehog (Hh), Wnt, Notch, and Hippo, and these have been widely implicated in the maintenance of CSCs \[[@R190], [@R191]\]. Considering that conventional chemotherapy only acts on active cells, and not on quiescent CSCs, targeting of characteristic signaling pathways of CSCs may represent a promising approach for GC therapy \[[@R191]\].

THE HEDGEHOG (HH) SIGNALING PATHWAY {#s15}
===================================

Sonic Hh molecules (Sonic, Indian, and Desert Hedgehog) are produced in gastric epithelial cells and they play a crucial role in the development and regulation of gastric epithelial cell differentiation and regeneration. They also have an important role in the maintenance of adult stem cells \[[@R191]--[@R194]\]. The Hh signaling pathway has recently been recognized as one of the most important signaling pathways in the cell, and thus, is a therapeutic target in cancer. In adults, mutations or deregulation of this pathway have been found to play a key role in both cell proliferation and differentiation, thereby leading to tumorigenesis or accelerated tumor growth in a wide variety of tissues. In addition, recent findings suggest that Hh signaling may also promote tumorigenesis in a paracrine manner from the tumor to the surrounding stroma, or in CSCs \[[@R195]\]. Overexpression of Patched (PTCH1), sonic Hh (SHH), Smoothened (SMO), Indian, GLI1, and GLI2 have been found with great frequency in GC cases (Table [2](#T2){ref-type="table"}). In particular, the SHH ligand has been found to be deregulated during the progression from inflammation to intestinal-type cancer, indicating that the Hh protein is involved in the early stages of gastric carcinogenesis \[[@R196], [@R197]\]. *In vitro*, Kim et al. \[[@R198]\] have demonstrated that overexpression of SHH and GLI1 occurs in a *H. pylori* CagA-dependent manner partly through activation of the NF-κB pathway in GC cells. Subsequently, they reported that GLI1 overexpression suppressed Wnt transcriptional activity and nuclear β- β-catenin accumulation, and these pathways contribute GC cell differentiation \[[@R199]\]. Crosstalk between the Hh and Wnt pathways was initially suggested by Yanai et al. \[[@R200]\] who reported the critical roles of these two pathways in the progression of GC. Interestingly, the Hh pathway may mediate crosstalk signaling with the KRAS-MEK-ERK signaling pathway in the regulation of cell proliferation in GC \[[@R201]\]. Emerging evidence further suggests that the SHH pathway is not only involved in the development of GC, but also in the progression, aggressiveness, and metastasis of this disease \[[@R202], [@R203]\]. Recently, expression of SHH, PTCH1, and GLI2 were found to be independently associated with poor survival \[[@R68], [@R204], [@R205]\]. In addition, Yoo et al. elucidated that the SHH pathway mediates cell invasion, metastasis, and lymphangiogenesis via activation of AKT, the epithelial-mesenchymal transition, and the MMP9 pathway in GC \[[@R203]\].

Several proteins in the Hh signaling pathway have been identified as potential drug targets for inhibiting aberrant Hh signaling. The first identified Hh pathway inhibitor, cyclopamine (a SMO inhibitor) has low affinity and poor bioavailability, and thus, more potent derivatives have been synthesized. Of the potential Hh signaling pathway targets, only the SMO antagonists have been tested in humans, including vismodegib, IPI-926, LDE-225, BMS-833923, and PF-04449913. In the initial studies of GC cell lines treated with cyclopamine and Gli transcription factor inhibitor (GANT61), cell survival, proliferation, migration, and colony formation were inhibited \[[@R206]--[@R208]\]. *In vivo* studies have subsequently demonstrated that cyclopamine significantly prevents tumor growth and development \[[@R208]\], while preclinical assays that combined chemotherapy with vismodegib (GDC-0449, SMO inhibitor) to treat a subpopulation of CD44+ gastric tumor stem cells were found to reverse resistance to conventional chemotherapy \[[@R209]\].

Vismodegib was approved by the FDA in 2012, particularly as a treatment for advanced stage and metastatic basal cell carcinoma (BCC) and for select patients with medulloblastoma \[[@R210], [@R211]\]. However, in a phase II clinical trial of patients with metastatic colorectal cancer, treatment with vismodegib exhibited no incremental benefit in combination with FOLFOX \[[@R212]\] or compared with standard FOLFOX or FOLFIRI plus bevacizumab therapies \[[@R213]\]. Currently, the clinical roles of vismodegib, LDE-225, and BMC-833923 in recurrent and metastatic advanced stage gastric adenocarcinomas are been evaluated. The results of two phase I/II clinical trials of SMO inhibitors in combination with conventional cytotoxic therapy, or with a PI3K inhibitor, for the treatment of advanced stage GC (BKM120) are also awaited (NCT00982592 and NCT01576666) \[[@R92]\]. Another interesting aspect is the recent observation that crosstalk and cooperation occurs between the Hh and Wnt, MAPK, and PI3K/AKT signaling pathways \[[@R200], [@R201], [@R203]\]. These results are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, LDE225, and BMS-833923 \[[@R214]\].

THE WNT SIGNALING PATHWAY {#s16}
=========================

The Wnt signaling pathway regulates cell proliferation, survival, morphology, migration, self-renewal in stem cells, and specification of cell fate during embryonic development. Wnt signaling also plays an important role throughout adult life by maintaining the homeostasis of tissues via the regulation of somatic stem cells in their niches \[[@R215]--[@R217]\]. Currently, Wnt signaling is divided into canonical and non-canonical pathways. In the former, Wnt signals (extracellular ligands, such as wnt-1) stabilize β-catenin, thereby leading to the activation of gene transcription based on interactions between β-catenin and transcription factors \[[@R218]\]. Accordingly, abnormal activation of the Wnt/β-catenin signaling pathway strongly correlates with tumorigenesis and malignant progression in a number of cancers, including colorectal, breast, lung, glioblastoma, prostate, melanoma, ovarian and gastric \[[@R217], [@R219]\]. Recently, a low abundance transcriptome analysis was performed for GC, and the Wnt/Hh pathway was found to be deregulated. Furthermore, the genes that exhibited the largest differential expression in the GC samples analyzed included: WISP1, FZD5 and its ligand WNT5, CTBP1, PTCH, and SFRP4 \[[@R220]\]. Moreover, increased expression of *WNT5A* (which leads to β-catenin -independent signaling) has been found to potentially correlate with poor clinical outcome for cases of melanoma and GC \[[@R217]\].

Despite the fact that the Wnt signaling pathway is more difficult to target compared with the Notch and Hh pathways, receptor/ligand interactions, cytosolic signaling components, and nuclear signaling components of the Wnt signaling pathway have been inhibited \[[@R221]\]. Furthermore, these inhibitors can be grouped into two classes, small-molecule inhibitors (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), the CBP/β-catenin antagonist, ICG-001) and biologic inhibitors (antibodies, RNA interference (RNAi), and recombinant proteins) \[[@R216]\]. The majority of these inhibitors are in the preclinical stages of development, except PRI-724 which has been evaluated in clinical trials for colorectal and pancreatic patients \[[@R222]\].

The Wnt/β-catenin signaling pathway also contributes to the regulation of CSCs \[[@R223], [@R224]\]. In the past few years, numerous groups have worked to isolate and characterize GC stem cells \[[@R183], [@R225]--[@R228]\]. Li et al. \[[@R188]\] showed that stem cell-like circulating tumor cells are associated with a poor prognosis in GC. Several groups are also trying to understand how intrinsic and extrinsic factors that regulate Wnt/β-catenin signaling coordinate with CSC states in different malignancies, including GC \[[@R219], [@R229]--[@R234]\]. Mao et al. \[[@R219]\] have recently reported that activation of Wnt1 signaling accelerates the proliferation of gastric CSCs, whereas salinomycin, the first agent identified as a selective inhibitor of breast CSCs, acts to inhibit gastric tumor growth by suppressing Wnt signaling in CSCs both *in vitro* and *in vivo*.

THE NOTCH SIGNALING PATHWAY {#s17}
===========================

The Notch signaling pathway affects cell proliferation, differentiation, apoptosis, and stem cell maintenance \[[@R235]\] via four Notch receptors (NOTCH1/2/3/4) that each has extracellular and transmembrane domains. The corresponding family of Notch ligands is comprised of JAG1/2 and DLL1/3/4 (DLL1/3/4). When these ligands bind the EGF-like repeat regions in the Notch receptors, a metalloprotease of the ADAM family executes a cleavage reaction \[[@R235]\]. Following the execution of a second intramembrane cleavage event by an γ-secretase complex, the intracellular domain of the Notch receptor is released (NotchIC or NICD). Upon translocation of this domain into the nucleus \[[@R236]\], its works as a transcriptional coactivator, thus regulating the expression of several target genes \[[@R237]\].

The Notch signaling pathway is involved in normal gastric mucosa development and mediates the differentiation of the gastric epithelium into foveolar glands \[[@R238]\]. However, higher levels of Notch receptors (e.g., NOTCH1/2/3) and Notch ligands (e.g., JAG1/2) have been detected in samples of gastric premalignant lesions and GC tissues \[[@R238], [@R239]\]. In a recent meta-analysis, NOTCH1 expression was found to be significantly higher in GC tissues than in normal tissues, especially in samples of intestinal metaplasia and well-differentiated intestinal-type GC, thereby suggesting a crucial role for NOTCH1 in both promoting the metaplastic transition and maintaining the proliferation of intestinalized cells \[[@R240]\]. The activated form of the NOTCH1 receptor has also been found to promote the formation of colonies and xenografted tumor growth of human stomach adenocarcinoma SC-M1 cells \[[@R240]\]. Furthermore, positive expression of Notch1 or Jagged1 protein has been proven to be associated with a poor prognosis and both have been found to be independent prognostic predictors in GC \[[@R240], [@R241]\]. These results are consistent with a role for *NOTCH1* as an oncogene in many solid malignancies. To date, mutated *NOTCH1* has only been detected in T-cell acute lymphoblastic leukemia, and not in other common human cancers, including GC \[[@R242]\]. Interestingly, GC patients with a larger tumor ( \> 5 cm), positive lymphovascular invasion, and distal metastasis had significantly higher expression rates of NOTCH1, thereby suggesting that NOTCH1 may also participate in tumor progression and metastasis of GC \[[@R240]\].

When JAG1 expression was compared between GC tissues and normal tissues, no significant difference was observed. In contrast, expression levels of DLL4 and HES1 have been found to be significantly higher in GC tissues than in normal tissues, with the levels of DLL4 being overexpressed in advanced stage GC patients. Levels of NOTCH2 and NOTCH3 expression have also exhibited significant overexpression in GC tissues compared to normal tissues. However, while no difference in NOTCH2 expression levels have been observed between intestinal-type and diffuse-type cancers, levels of NOTCH3 and JAG2 are significantly higher in the intestinal-type group. It has been demonstrated that activation of Notch2 signaling promotes cell proliferation and xenograft tumor \[[@R240]\].

Notch receptor cleavage can be disrupted by γ-secretase inhibitors (GSIs) such as: L685, RO4929097, PF-03084014, and DAPT. Correspondingly, GSIs have been shown to inhibit cell growth and to induce apoptosis in hepatoma, breast, pancreatic, and myeloma cancers \[[@R243]--[@R245]\]. Given that the Notch signaling pathway participates in many processes of cellular physiology, it has been hypothesized that inactivation of γ-secretases can lead to pathological dysfunction of various tissues and organs. However, GSIs do not only target Notch signaling proteins. GSIs also target proteases, and therefore, may have widespread adverse effects *in vivo* \[[@R245], [@R246]\]. In GC cells, inhibition of the NOTCH2 pathway by γ-secretase antagonists did not lead to growth arrest or cell death \[[@R238]\]. However, this may be due to compensation from other signaling pathways in response to suppressed Notch signaling activity \[[@R238]\].

Currently, there are two γ-secretases that are being evaluated in phase I clinical trials. RO4929097 is being evaluated in patients with breast cancer, pancreatic cancer, leukemia, sarcoma, melanoma, or other solid tumors (NCT01131234), whereas PF-03084014 is being tested in patients with advances cancer and leukemia (NCT00878189) \[[@R92]\].

THE HIPPO SIGNALING PATHWAY {#s18}
===========================

In mammals, the Hippo signaling pathway provides tumor-suppressor signaling involved in regulation of diverse cellular processes such as proliferation, apoptosis, survival, migration and differentiation \[[@R247]\]. In recent years, growing evidence has pointed towards an oncogenic role for the Hippo signaling pathway in human cancer, including GC. While the key components and upstream regulators of the Hippo signaling pathway (MST1/2, LATS1, SAV1, MOB, FAT, NF2, and FDM6) are mostly considered to participate as tumor suppressors, downstream mediators in this pathway (TAZ, YAP1, and TEAD) are mostly involved in oncogenic events. The first report of Hippo pathway deregulation in gastric epithelial tumorigenesis was described by Lam-Himlin et al. \[[@R248]\], where YAP1 expression in the cytoplasm and nucleus were found to significantly increase in high-grade dysplasia, adenocarcinoma, and metastasis gastric disease. Positive expression of YAP1 was also detected in 79.2% of GCs, 47.1% of dysplasia cases, and 15.0% of normal gastric tissues \[[@R249]\]. Nuclear overexpression of YAP1 has been described as an independent biomarker for poor survival, especially in patients with early stage GC \[[@R249], [@R250]\]. Additionally, Xu et al. \[[@R251]\] showed that expression of MST1/2 and LATS1, two principal suppressor genes of this pathway, were down-regulated in GC compared with normal gastric epithelium and adenoma. Moreover, the expression levels of SAV1 and LATS1 in GC patients with lymph node metastasis were significantly lower than those in GC patients without lymph node metastasis. Knockdown of YAP1 has also resulted in a significant reduction in cell proliferation, anchorage-dependent colony formation, cell invasion, and cell motility. Meanwhile, ectopic YAP1 expression induced a more invasive phenotype and accelerated cell growth in both *in vitro* and *in vivo* assays \[[@R249]\]. Taken together, these findings suggest that inhibition of YAP1 may represent a prognostic biomarker and a potential therapeutic target for GC.

The identification of small molecule inhibitors of YAP1 is also an active area of study. In a screening of more than 3300 drugs by Liu-Chittenden et al. \[[@R252]\], the porphyrin family of proteins, including verteporfin (VP), hematoporphyrin, and protoporphyrin IX, were identified as YAP1 inhibitors. When livers were treated with VP, overgrowth induced by YAP overexpression, or by inactivation of NF2, was inhibited \[[@R252], [@R253]\], thereby demonstrating the therapeutic potential of disrupting YAP1/TAZ-TEAD interactions. In a recent phase I/II study, the feasibility and safety of using VP photodynamic therapy for the treatment of locally advanced stage pancreatic cancer was demonstrated \[[@R254]\]. However, despite these promising data, it remains to be determined whether inhibitors of YAP1 will be effective for the treatment of GC.

CONCLUDING REMARKS {#s19}
==================

Emerging data from high-throughput technologies have provided valuable insight into the molecular classification and intracellular pathways that are relevant to GC, and this facilitates the development of novel strategies for treating GC. However, chemotherapy resistance remains a significant challenge in treating GC due to the heterogeneity of these tumors and their CSC component that lead to high rates of recurrence. New strategies should seek to intervene in cancer or tissue-specific targets, enabling the protection of normal cells as well \[[@R85]\]. Thus, there is a critical need for therapies that are based on genetic and epigenetic aberrations that modulate different signaling pathways, or combinations of different signaling pathways, in various types of cancer, particularly GC. As a result, the development of more effective agents and the identification biomarkers that can be used for the diagnosis, prognosis, and therapy of patients who might benefit from specific targeted therapies can be elucidated (Figure [3](#F3){ref-type="fig"}).

Despite the ongoing development of drugs for the treatment of unresectable or metastatic gastric adenocarcinoma, the overall prognosis for these diseases remains poor. Moreover, many of these strategies are generally only applicable to a limited number of patients. To date, advances in personalized medicine have improved therapeutic responses in advanced stage ERBB2-positive GC patients treated with trastuzumab. However, this therapy has benefited only \~15% of these patients. New molecules that target the VEGF, PI3K/AKT/mTOR, and MET signaling pathways are also under investigation, and promising results have been obtained. Novel insights regarding signaling pathways that regulate gastric CSCs such as Hh, Notch, and Hippo, and the drugs that block these pathways, also have the potential to improve treatment responses to targeted therapy alone, or in combination with conventional cytotoxic therapy. Therefore, a new paradigm in GC research that involves the implementation of strategies and clinical trials in which patients can be classified based on molecular characteristics or molecular subtypes in order to select the most appropriate and target-specific therapies for patients with advanced stage GC is recommended.
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